Effect of carvedilol on heart failure in patients with a functionally univentricular heart

Circulation Journal

Volumn 75, Issue 6, 2011, Pages 1394-1399

  Ishibashi, Naoko ^a   Park, In Sam ^a   Waragai, Tadashi ^a   Yoshikawa, Tadahiro ^a   Murakami, Yasuo ^a   Mori, Katsuhiko ^a   Mimori, Shigekazu ^a   Ando, Makoto ^a   Takahashi, Yukihiro ^a   Doi, Shouzaburo ^b   Mizutani, Shuuki ^b   Nakanishi, Toshio ^c  

^a SAKAKIBARA HEART INSTITUTE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Carvedilol; Heart failure; Univentricular heart

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; FUROSEMIDE; HYDROCHLOROTHIAZIDE;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL ENDOCARDITIS; CAVOPULMONARY CONNECTION; CENTRAL VENOUS PRESSURE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFECT; DRUG WITHDRAWAL; FOLLOW UP; FONTAN PROCEDURE; GLENN SHUNT; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART RIGHT VENTRICLE; HEART SINGLE VENTRICLE; HEART VALVE STENOSIS; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; INFANT; MAJOR CLINICAL STUDY; NORWOOD PROCEDURE; POSTOPERATIVE INFECTION; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SYSTEMIC CIRCULATION;

ADOLESCENT; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; CARBAZOLES; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; FONTAN PROCEDURE; HEART DEFECTS, CONGENITAL; HEART FAILURE; HUMANS; INFANT; JAPAN; MALE; PROPANOLAMINES; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT; YOUNG ADULT;

EID: 79957729449     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0845     Document Type: Article

References (37)

1. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-1036.
2. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979; 1: 1374-1376.
3. Mortara A, Rovere M, Pinna G, Maestri R, Capomolla S, Cobelli F. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure. J Am Coll Cardiol 2000; 36: 1612-1618.
4. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-1667.
5. Packer M, Bristow M, Cohn J, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-1355.
6. Whorlow S, Krum H. Meta-Analysis of effect of beta-blocker therapy on mortality in patients with New York heart association class IV chronic congestive heart failure. Am J Cardiol 2000; 86: 886-889.
7. Packer M, Coats A, Fowler M, Katus HA, Krum H, Mohacsi P, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
8. Packer M, Colucci W, Sackner-Bernstein J, Liang CS, Goldscher DA, Freeman I, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE trial [Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise]. Circulation 1996; 94: 2793-2799.
9. Colucci W, Packer M, Bristow M, Gilbert EM, Cohn JN, Fowler MB, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure: US Carvedilol Heart Failure Study Group. Circulation 1996; 94: 2800-2806.
10. Buchhorn R, Bartmus D, Siekmeyer W, Hulpe-Wette M, Schulz R, Bursch J. Beta-blocker therapy of severe congestive heart failure in infants with left to right shunts. Am J Cardiol 1998; 81: 1366-1368.
11. Bruns L, Chrisant M, Lamour J, Shaddy RE, Pahl E, Blume ED, et al. Carvedilol as therapy in pediatric heart failure: An initial multicenter experience. J Pediatr 2001; 138: 505-511.
12. Laer S, Mir T, Behn F, Eiselt H, Venzke A, Meibohm B, et al. Carvedilol therapy in pediatric patients with congestive heart failure: A study investigating clinical and pharmacokinetic parameters. Am Heart J 2002; 143: 916-922.
13. Giardini A, Formigari R, Bronzetti G, Prandstraller D, Donti A, Bonvicini M, et al. Modulation of neurohormonal activity after treatment of children in heart failure with carvedilol. Cardiol Young 2003; 13: 333-336.
14. Blume E, Canter C, Spicer R, Gauvreau K, Colan S, Jenkins KJ. Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol 2006; 27: 336-342.
15. Shaddy R, Boucek M, Hsu D, Boucek RJ, Canter CE, Mahony L, et al. Carvedilol for children and adolescents with heart failure: A randomized controlled trial. JAMA 2007; 298: 1171-1179.
16. Ishibashi N, Park I, Takahashi Y, Nishiyama M, Murakami Y, Mori K, et al. Effectiveness of carvedilol for congestive heart failure that developed long after modified Fontan operation. Pediatr Cardiol 2006; 27: 473-475.
17. Olsen S, Gilbert E, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study. J Am Coll Cardiol 1995 25: 1225-1231.
18. Groenning B, Nilsson J, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000; 36: 2072-2080.
19. Kubo H, Margulies K, Piacentino V 3rd, Gaughan JP, Houser SR. Patients with end-stage congestive heart failure treated with β- adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation 2001; 104: 1012-1018.
20. Reiken S, Wehrens X, Vest J, Barbone A, Klotz S, Mancini D, et al. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 2003; 107: 2459-2466.
21. Keith M, Geranmayegan A, Sole M, Kurian R, Robinson A, Omran AS, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998; 31: 1352-1356.
22. Flesch M, Maack C, Cremers B, Bäumer AT, Südkamp M, Böhm M. Effect of beta-blockers on free radical-induced cardiac contractile dysfunction. Circulation 1999; 100: 346-353.
23. Arumanayagam M, Chan S, Tong S, Sanderson JE. Antioxidant properties of carvedilol and metoprolol in heart failure: A doubleblind randomized controlled trial. J Cardiovasc Pharmacol 2001; 37: 48-54.
24. Gilbert E, Abraham W, Olsen S, Hattler M, White M, Mealy P, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94: 2817-2825.
25. Prabhu S, Chandrasekar B, Murray D, Freeman GL. Beta-adrenergic blockade in developing heart failure: Effects on myocardial inflammatory cytokines, nitric oxide and remodeling. Circulation 2000; 101: 2103-2109.
26. Dandona P, Karne R, Ghanim H, Hamouda W, Aljada A, Magsino CH Jr. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000; 101: 122-124.
27. Nishiyama K, Tsutamoto T, Yamaji M, Kawahara C, Yamamoto T, Fujii M, et al. Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure: Special reference to ranscardiac gradient of norepinephrine. Circ J 2009; 73: 2270-2275.
28. Lowes B, Gill E, Abraham W, Larrain JR, Robertson AD, Bristow MR, et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 1999; 83: 1201-1205.
29. Capomolla S, Febo O, Gnemmi M, Riccardi G, Opasich C, Caporotondi A, et al. Beta-blockade therapy in chronic heart failure: Diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J 2000; 139: 596-608.
30. Yamaji M, Tsutamoto T, Tanaka T, Kawahara C, Nishiyama K, Yamamoto T, et al. Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure. Circ J 2009; 73: 1067-1073.
31. Law Y, Ettedgui J, Beerman L, Maisel A, Tofovic S. Comparison of plasma B-type natriuretic peptide levels in single ventricle patients with systemic ventricular heart failure versus isolated cavopulmonary failure. Am J Cardiol 2006; 98: 520-524.
32. Anderson P, Sleeper L, Mahony L, Colan SD, Atz AM, Breitbart RE, et al; Pediatric Heart Network Investigators. Contemporary outcomes after the Fontan procedure; A Pediatric Heart Network multicenter study. J Am Coll Cardiol 2008; 52: 85-98.
33. Berry J, Askovich B, Shaddy R, Hawkins JA, Cowley CG. Prognostic value of B-type natriuretic peptide in surgical palliation of children with single-ventricle congenital heart disease. Pediatr Cardiol 2008; 29: 70-75.
34. Koch A, Zink S, Singer H, Dittrich S. B-type natriuretic peptide levels in patients with functionally univentricular hearts after total cavopulmonary connection. Eur J Heart Failure 2008; 10: 60-62.
35. Hsu J, Oishi P, Keller R, Chikovani O, Karl TR, Azakie A, et al. Perioperative B-type natriuretic peptide levels predict outcome after bidirectional cavopulmonary anastomosis and total cavopulmonary connection. J Thorac Cardiovasc Surg 2008; 135: 746-753.
36. Larsson D, Meurling C, Holmqvist F, Waktare JE, Thilen UJ. The diagnostic and prognostic value of brain natriuretic peptide in adults with a systemic morphologically right ventricle or Fontan-type circulation. Int J Cardiol 2007; 114: 345-351.
37. Auerbach SR, Richmond ME, Lamour JM, Blume ED, Addonizio LJ, Shaddy RE, et al. BNP levels predict outcome in pediatric heart failure patients. Circ Heart Fail 2010; 3: 606-611.